Lv5
970 积分 2026-01-06 加入
Efficacy and safety of a biased GLP-1 receptor agonist ecnoglutide in adults with overweight or obesity: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
1个月前
已完结
Effects of CT-388, a once-weekly signaling-biased dual GLP-1/GIP receptor agonist, on weight loss and glycemic control in preclinical models and participants with obesity
1个月前
已完结
794-P: MET-097: Preclinical Characterization of a Potent and Ultra-Long-Acting GLP-1 Receptor Agonist
1个月前
已关闭
P0033 Repositioning dual GLP-1/GIP receptor agonists for the treatment of colitis and colitis-associated cancer (CAC)
1个月前
已完结
Peptide Hormones and Bile Acids Shaping Immune Tolerance of the Liver: Implications and Applications
1个月前
已完结
Glucagon-Like Peptide-1 (GLP-1) receptor agonists in rheumatology: A review of current evidence and future directions
2个月前
已完结
REPOSITIONING DUAL GLP-1/GIP RECEPTOR AGONISTS FOR THE TREATMENT OF COLITIS AND COLITIS-ASSOCIATED TUMORIGENESIS
2个月前
已完结
Gut microbiota perturbation and systemic inflammation are associated with salcaprozate sodium (SNAC)-enabled oral semaglutide delivery
2个月前
已关闭
Peptide Hormones and Bile Acids Shaping Immune Tolerance of the Liver: Implications and Applications
2个月前
已完结
Anorexigenic and anti-inflammatory signaling pathways of semaglutide via the microbiota–gut––brain axis in obese mice
2个月前
已完结
皖公网安备34019202002308
